CONCLUSION: Based on this experience, the protocol recommends Bup/Nx for pain only when baseline opioid doses are within bounds that reduce AEs at transition and incorporates dose flexibility to further reduce risks. This protocol warrants further testing.
PMID: 23264315 [PubMed – indexed for MEDLINE] (Source: Journal of Opioid Management)
Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
Call 1 (888) 460-6556 to speak with a counselor.
